LEMBAS BIO LTD

Based in Israel, Lembas develops science-driven supplements and functional ingredients aimed at enhancing metabolic health and supporting weight management through natural formulations. Lembas Bio Ltd focuses on innovative solutions in nutrition, having been founded in Israel in 2024. The company recently secured USD 3. 6 mn in pre-seed funding in June 2025, led by Flora Ventures, with participation from multiple investors.

There are no mentions of significant pivots or subsidiaries, and the founding team details are not available. Lembas specializes in developing innovative, science-backed supplements and functional ingredients designed to support healthy weight management and overall metabolic health. The company's core offerings are based on a unique blend of natural, scientifically tested ingredients that promote satiety without the need for prescriptions or invasive procedures. These products are engineered to seamlessly integrate into everyday food and beverage formats, including bars, shakes, snacks, and supplements, thereby addressing the growing consumer demand for convenient, effective health solutions.

Lembas targets various markets including North America and Europe, catering to a wide range of clients within the food, beverage, and wellness sectors. The end users of Lembas products include health-conscious consumers seeking effective weight management solutions without the complications associated with traditional dietary approaches. Lembas generates revenue through partnerships with companies in the supplement, food, beverage, and wellness industries, facilitating the development and distribution of its functional ingredients. The company's business model is centered around a B2B structure, where they provide their proprietary formulations to brands that integrate Lembas ingredients into their product lines.

Transactions typically occur through collaboration agreements, where partners may pay for ingredient access and formulation development. Lembas offers a range of products, with particular emphasis on their flagship ingredients known for their unique properties supporting metabolism and satiety. Pricing structures for these partnerships are established on a case-by-case basis, reflecting the specific needs and scales of their partners within the marketplace. In June 2025, Lembas Bio Ltd raised USD 3.

6 mn in pre-seed funding, which will be utilized to develop peptide-based ingredients for weight management and to partner with food brands to create GLP-1-targeting products. The company plans to launch several new product offerings in the upcoming year, focusing specifically on enhancing their ingredient portfolio. Additionally, Lembas aims to expand its reach into new geographic regions, particularly targeting sectors in North America and Europe by the end of 2026.